ENYO Pharma
Phase 2Our mission is to develop highly differentiated therapeutics for improving the quality of life of patients with impaired kidney function.
Founded
2014
Focus
Small Molecules
About
Our mission is to develop highly differentiated therapeutics for improving the quality of life of patients with impaired kidney function.
Funding History
3Total raised: $108.5M
Series C$60MSofinnova PartnersJan 15, 2021
Series B$35MAndera PartnersJul 15, 2018
Series A$13.5MSofinnova PartnersJun 15, 2015
Company Info
TypePrivate
Founded2014
LocationLyon, France
StagePhase 2
Contact
Sectors
SIMILAR COMPANIES
4P-Pharma
Phase 2 · Lille
Patheon
Pre-clinical · Lyon
ABL Diagnostics
Pre-clinical · Strasbourg
Acticor Biotech
Pre-clinical · Paris
Adjuvatis
Pre-clinical · Lyon
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile